June 2026
MDMA
What June 2026's 16 new studies found, synthesized from the papers below. All MDMA research →
The synthesis
Synthesized from 16 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.
In June 2026, MDMA research showed that a booster dose prolongs subjective effects without increasing peak intensity, and that MDMA-assisted therapy produced large reductions in social anxiety symptoms in an open-label trial. A systematic review and meta-analysis confirmed a moderate-to-large effect of MDMA-assisted psychotherapy for PTSD, but a commentary highlighted unresolved challenges including blinding difficulties, expectancy effects, and limited mechanistic clarity. The evidence is promising but constrained by small samples, open-label designs, and unresolved methodological issues.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study 2026 | double-blind, randomized, placebo-controlled, crossover study | 25 | Supports | A booster dose of MDMA prolonged subjective drug effects compared to a single dose (5.6 vs 4.6 hours) without increasing peak effects, but acute and subacute adverse effects were more common. |
| MDMA-Assisted Therapy for Social Anxiety Disorder: A Randomized, Open-label, Wait-list Controlled Trial 2026 | randomized, open-label, wait-list controlled trial | 20 | Supports | MDMA-assisted therapy produced a large reduction in social anxiety symptoms (mean difference -43.3 on LSAS, Hedge's g=2.8) compared to waitlist, with no serious adverse events. |
| Psychedelic-Assisted Psychotherapy for the Treatment of PTSD: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | 358 | Supports | MDMA-assisted psychotherapy demonstrated a significant moderate-to-large reduction in PTSD symptom severity with negligible heterogeneity, and participants were more likely to achieve clinical response and loss of PTSD diagnosis. |
| From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026 | commentary | Mixed | The commentary acknowledges MDMA's therapeutic promise but emphasizes unresolved challenges including blinding difficulties, expectancy effects, absence of active comparators, limited mechanistic clarity, and safety monitoring concerns. | |
| Understanding How Trait Negative Emotionality (NEM) Influences Social Connectedness and Responses to ± 3,4-Methylenedioxymethamphetamine (MDMA) 2026 | within-subject, double-blind, placebo-controlled secondary analysis | 30 | Mixed | Trait negative emotionality showed a trend-level association with greater MDMA-induced peak friendliness change and predicted oxytocin release after accounting for sex, but findings are preliminary due to small sample. |
| Monday mood decline after weekend ecstasy use: A retrospective analysis of daily diary reports. 2026 | retrospective analysis of daily diary reports | 17 | Opposes | Weekend ecstasy use was associated with lower Monday mood, but this effect was largely accounted for by increased time in bed, suggesting recovery-related behaviors rather than direct drug effects. |
| Consumo recreativo de MDMA: un estudio sobre jóvenes en España 2026 | mixed-methods survey and qualitative | 1412 | Unclear | MDMA was predominantly consumed in recreational contexts (80.6% past-year prevalence), with low adherence to recommended dose intervals (27.5%) and frequent co-use with alcohol and cannabis. |
| Protocol for a qualitative mechanistic study of MDMA with a sample of psychoanalytic psychotherapists: A phenomenological investigation 2026 | protocol for qualitative mechanistic study | 25 | Unclear | This protocol describes an open-label qualitative study to investigate psychological mechanisms of MDMA-assisted psychotherapy, but no results are reported. |
| MDMA-induced CYP2D6 inhibition: concentration-dependent variability using dextromethorphan as a probe 2026 | preclinical animal study | 32 | Opposes | MDMA inhibited CYP2D6 in rats, with concentration-dependent effects; inhibition was observed at 1 hour but not at 1 week or 1 month at therapeutic concentrations, but persisted at saturated concentrations. |
| The Role of the Basolateral and Central Amygdala During Heroin Withdrawal and 3,4-Methylenedioxymethamphetamine Administration 2026 | preclinical animal study | Mixed | MDMA did not exacerbate heroin withdrawal-induced weight loss, and showed region-specific effects on astrocytic activation in the basolateral amygdala, suggesting interactive effects with heroin. | |
| Shifting Patterns in Ecstasy Use: Increasing Detection of MDA in Forensic Seizures and Toxicological Cases in Southern Brazil 2026 | forensic and toxicological analysis | Unclear | MDA was detected in 31.1% of seized ecstasy samples, surpassing MDMA (25.6%), with a marked rise after 2020, indicating a shift in ecstasy use patterns in Brazil. | |
| Semi-Quantitative Estimation of MDMA Tablet Dosage and Cocaine/Ketamine Purity Using a Simple to Operate Field-Portable Device 2026 | device development and validation study | 62 | Unclear | A field-portable device using deep learning achieved 98% accuracy in classifying MDMA tablet dosage brackets and 96% accuracy for cocaine/ketamine purity estimation. |
| Psychometric validation of the French version of the five-dimensional altered states of consciousness questionnaire (5D-ASC) and associated 11 OAV subscales. 2026 | psychometric validation study | 777 | Unclear | The French version of the 5D-ASC questionnaire showed good internal consistency (α=0.95) and acceptable fit for the 11-subscale structure, supporting its use in francophone research. |
| Blinding, Expectancy, and the Active Placebo Paradox in MDMA Research. 2026 | theoretical/commentary | Unclear | This article discusses blinding, expectancy, and the active placebo paradox in MDMA research, but no empirical data are reported. | |
| Clinical and non-clinical use of MDMA. 2026 | theoretical/commentary | Unclear | This article discusses clinical and non-clinical use of MDMA, but no empirical data are reported. | |
| VA launches MDMA‐assisted mental health therapy trial 2026 | news release | Unclear | The VA has launched a clinical trial of MDMA-assisted therapy for PTSD and alcohol use disorder, but no results are reported. |
A booster dose of MDMA prolonged subjective drug effects compared to a single dose (5.6 vs 4.6 hours) without increasing peak effects, but acute and subacute adverse effects were more common.
double-blind, randomized, placebo-controlled, crossover study Sample size: 25
MDMA-assisted therapy produced a large reduction in social anxiety symptoms (mean difference -43.3 on LSAS, Hedge's g=2.8) compared to waitlist, with no serious adverse events.
randomized, open-label, wait-list controlled trial Sample size: 20
MDMA-assisted psychotherapy demonstrated a significant moderate-to-large reduction in PTSD symptom severity with negligible heterogeneity, and participants were more likely to achieve clinical response and loss of PTSD diagnosis.
systematic review and meta-analysis Sample size: 358
The commentary acknowledges MDMA's therapeutic promise but emphasizes unresolved challenges including blinding difficulties, expectancy effects, absence of active comparators, limited mechanistic clarity, and safety monitoring concerns.
commentary
Trait negative emotionality showed a trend-level association with greater MDMA-induced peak friendliness change and predicted oxytocin release after accounting for sex, but findings are preliminary due to small sample.
within-subject, double-blind, placebo-controlled secondary analysis Sample size: 30
Weekend ecstasy use was associated with lower Monday mood, but this effect was largely accounted for by increased time in bed, suggesting recovery-related behaviors rather than direct drug effects.
retrospective analysis of daily diary reports Sample size: 17
MDMA was predominantly consumed in recreational contexts (80.6% past-year prevalence), with low adherence to recommended dose intervals (27.5%) and frequent co-use with alcohol and cannabis.
mixed-methods survey and qualitative Sample size: 1412
This protocol describes an open-label qualitative study to investigate psychological mechanisms of MDMA-assisted psychotherapy, but no results are reported.
protocol for qualitative mechanistic study Sample size: 25
MDMA inhibited CYP2D6 in rats, with concentration-dependent effects; inhibition was observed at 1 hour but not at 1 week or 1 month at therapeutic concentrations, but persisted at saturated concentrations.
preclinical animal study Sample size: 32
MDMA did not exacerbate heroin withdrawal-induced weight loss, and showed region-specific effects on astrocytic activation in the basolateral amygdala, suggesting interactive effects with heroin.
preclinical animal study
MDA was detected in 31.1% of seized ecstasy samples, surpassing MDMA (25.6%), with a marked rise after 2020, indicating a shift in ecstasy use patterns in Brazil.
forensic and toxicological analysis
A field-portable device using deep learning achieved 98% accuracy in classifying MDMA tablet dosage brackets and 96% accuracy for cocaine/ketamine purity estimation.
device development and validation study Sample size: 62
The French version of the 5D-ASC questionnaire showed good internal consistency (α=0.95) and acceptable fit for the 11-subscale structure, supporting its use in francophone research.
psychometric validation study Sample size: 777
This article discusses blinding, expectancy, and the active placebo paradox in MDMA research, but no empirical data are reported.
theoretical/commentary
This article discusses clinical and non-clinical use of MDMA, but no empirical data are reported.
theoretical/commentary
The VA has launched a clinical trial of MDMA-assisted therapy for PTSD and alcohol use disorder, but no results are reported.
news release
Points of agreement
- MDMA-assisted therapy shows promising efficacy signals for PTSD and social anxiety in clinical trials.
- Booster dosing prolongs subjective effects of MDMA without increasing peak intensity.
- Recreational MDMA use is associated with low adherence to harm reduction practices and frequent polysubstance use.
- Methodological challenges such as blinding difficulties and expectancy effects are acknowledged across multiple sources.
Conflicts
- The systematic review reports a moderate-to-large effect for MDMA in PTSD, while the commentary emphasizes that the evidence base is constrained by major limitations including blinding and expectancy.
- Laboratory studies find minimal residual mood effects, but naturalistic data show a Monday mood decline that may be driven by recovery behaviors rather than direct drug effects.
Gaps
- Long-term durability of treatment gains from MDMA-assisted therapy is not established.
- Mechanistic understanding of MDMA's therapeutic effects remains limited, especially psychological and relational processes.
- Safety data are heterogeneous and insufficiently characterized, particularly for long-term outcomes.
- Blinding integrity and expectancy effects are not adequately addressed in most trials.
- Generalizability is limited by predominantly white, non-clinical samples in many studies.
- Dose optimization and the role of booster doses in clinical settings require further investigation.